Psychiatric-Mental Health Nursing Monthly News Digest July 2026
Summary: The July 2026 psychiatric-mental health nursing monthly news digest includes new treatment guidance, medication management resources, and digital mental health innovations, care delivery, workforce, community mental health developments, new research and publications, and more.
Clinical Practice & Care Delivery
- Medscape published a July 10 psychiatry roundup summarizing recent FDA actions related to therapeutics for psychiatric illness, including patient education, adverse effect monitoring, prescribing collaboration, and care planning for individuals receiving psychiatric treatments.
- SAMHSA Examines Wearables and Digital Mental Health Tools: A new SAMHSA advisory examines the use of wearables, apps, digital therapeutics, AI-enabled screening tools, chatbots, and other technologies in mental health.
- Becker’s reviewed early implementation issues six weeks after California’s emergency nurse-to-patient staffing ratios for freestanding acute psychiatric hospitals took effect on June 1.
- New Guidance Addresses Therapeutic Drug Monitoring: The TDM Group of the Association for Neuropsychopharmacology and Pharmacopsychiatry (AGNP) has released updated consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology.
Research & Evidence
- New CDC Dashboard Offers Local Suicide and Overdose Data: A new CDC dashboard brings together mortality data on suicide, drug overdose, homicide, and firearm injury. Users can explore provisional and final data at the national, state, county, and, where available, census-tract levels.
- JAMA Network highlights cross-sectional study of 5,559 U.S. mental health treatment facilities found that 77.5% of child-serving facilities offered telehealth services and 56.1% offered telehealth-based medication management.
- JAMA Psychiatry: Addressing Antipsychotic-Associated Weight Gain: A systematic review and network meta-analysis combined 95 randomized trials involving 5,898 people with schizophrenia-spectrum disorders. Semaglutide, liraglutide, topiramate, metformin, and exenatide were associated with the greatest weight reductions compared with placebo.
- New in the July/August issue of the Journal of the American Psychiatric Nurses Association:
- Sensory Rooms and Depression: In a randomized crossover trial involving 20 adults with depression, a 30-minute sensory-room session increased resting vagal activity and reduced vagal reactivity to auditory stimulation compared with static seated activities.
- Supporting Adolescents’ Help-Seeking: A study of high school students and their caregivers found that adolescents’ depressive symptoms and personal stigma, along with caregivers’ attitudes toward seeking professional help, were among the strongest predictors of adolescents’ help-seeking attitudes.
- Chronic Pain and Suicidality Among Black Women: A discussion paper examines culturally relevant factors shaping Black women’s experiences with chronic pain and suicidality.
Published July 2026.
This summary was informed by human-guided AI tools. Readers are encouraged to review the supporting links for full information.
